Shares of Hims & Hers Health Inc. (HIMS) surged to a record high on Friday, soaring 26.35% as investors cheered the company's raised revenue forecast and plans to capitalize on the booming weight loss drug market.
The telehealth firm, which provides access to prescription medications and other health products, raised its full-year revenue guidance to $1.46-$1.47 billion from $1.37-$1.40 billion last week. This upward revision came as HIMS announced it will add a generic version of Novo Nordisk's popular diabetes and weight loss drug liraglutide to its platform in 2025.
With demand for weight loss drugs skyrocketing and leading to shortages, HIMS is well-positioned to benefit from its ability to produce generic alternatives under U.S. regulations. The company's move to enter this lucrative market has investors bullish on its growth prospects, driving shares up 213% year-to-date, significantly outperforming the broader market.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。